1. Investigación
Permanent URI for this communityhttps://hdl.handle.net/10637/1
Search Results
- Protocolo de obtención de Plasma Rico en Plaquetas (PRP) en el gato ("Felis silvestris catus") y su relación con enfermedades víricas felinas (Leucemia e Inmunodeficiencia)
2024-03-04 PRGF®-Endoret® se caracteriza por una concentración moderada de PLT y la ausencia de glóbulos rojos y leucocitos. El objetivo de este trabajo es estandarizar un protocolo de obtención de PRP para el gato y estudiar cómo la presencia de enfermedades virales como la leucemia (FeLV) y la inmunodeficiencia felina (VIF) podrían influir en su calidad y composición. Se incluyeron en el estudio 30 gatos sanos y se recogieron 3 tubos de 9 ml de sangre y se centrifugaron siguiendo diferentes protocolos: 255 g, 260 gy 265 g durante 10 minutos. Los resultados demostraron que el proceso de centrifugación a 265 g durante 10 minutos logró una concentración óptima de PLT, sin presencia de leucocitos. Respecto al VPM, fue significativamente mayor en la sangre basal que en las fracciones PRP y PPP. Las concentraciones de PDGF-BB y TGF-ß1 fueron estadísticamente mayores en la fracción PRP que en la fracción PPP. Posteriormente, se aplicó el protocolo estandarizado a 11 gatos positivos para FeLV y 16 gatos positivos para FIV. La concentración de PLT en gatos FeLV no alcanzó el mínimo requerido por la tecnología PRGF®-Endoret®, sin embargo, los valores se acercaron a los de gatos sanos. Por otro lado, el protocolo estandarizado no fue reproducible en gatos FIV.
- Characterization of platelet rich plasma in feline immunodeficiency virus-infected cats: cell, and PDGF-BB and TGF-ß1 growth factor analysis
2024-03 Autologous platelet-rich plasma (PRP) contains growth factors (GFs) that modulate the expression of inflammatory cells; thus, these products could be considered a good strategy to favor tissue regeneration in feline immunodeficiency (FIV) positive cats. However, there is no scientific documentation on obtaining PRP in FIV-positive cats. Authors hypothesized that PRP can be obtained in FIV cats following the PRGF®-Endoret® methodology. The objectives of this study were to compare the platelet, erythrocyte, and leukocyte concentration between whole blood (WB) and the PRP; and determine the concentration of platelet-derived growth factor BB (PDGF-BB) and transforming growth factor β1 (TGF-β1) in FIV-positive cats. Sixteen adults FIV-positive asymptomatic cats were included in the study. WB samples were drawn and the PRP was obtained by centrifugation at 265g for 10 min. Erythrocyte and leukocyte, platelets, and mean platelet volume (MPV) were determined both in WB and in PRP. PDGF-BB and TGF-β1 concentrations were additionally determined in PRP. Platelet concentration increased 1.1 times in PRP fraction compared to WB, but no significant differences were reported. MPV was statistically higher in WB than in PRP (p = 0.001). Erythrocytes and leukocytes counts were decreased by 99% and 92%, respectively in the PRP fraction (p < 0.001). Regarding TGF-ß1, a higher concentration was shown in the PRP (p < 0.02). Although the product obtained could not be classified as PRP according to the PRGF®-Endoret® methodology, based on the drastic reduction of RBC and WBC, the PLT concentrate is of high purity.
- Evaluation of Platelet-Rich Plasma by means of PRGF®-Endoret® protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
2023-01-26 Introduction: Feline leukemia virus (FeLV) is a chronic disease that leads to the weakening of a cat's immune system. Platelet-rich plasma (PRP) offers therapeutic effects for multiple diseases, the use of PRP and growth factors (GFs) determination could be an alternative treatment to improve the quality of life in these patients. The objectives of this study were to determine and compare the concentration of platelets (PLTs), red blood cells (RBCs) and white blood cells (WBCs) between samples of whole blood (WB), PRP and platelet-poor plasma (PPP) fractions, and to evaluate the concentration of platelet-derived growth factor BB (PDGF-BB) and transforming growth factor β1 (TGF-β1) in both fractions in FeLV cats using a PRGF®-Endoret® protocol previously standardized in this species. Methods: WB was collected from 11 asymptomatic FeLV-positive cats. PRP and PPP was obtained following PRGF®-Endoret® technology according to centrifugation at 265 g for 10 min. Cellular components, RBCs, WBCs, PLTs, and the PDGF-BB and TGF-β1 concentrations in PRP and PPP fractions were determined. Results: PLT in the PRP fraction was statistically higher than WB and PPP fraction, with no statistical differences between WB and PPP. PLT concentration increased 1.4 times in PRP fraction compared to WB. Mean platelet volume (MPV) did not differ significantly between the WB, PRP, and PPP fractions. Compared to WB, the absolute numbers of RBCs and WBCs were decreased by 99% and more than 95% in the PRP and PPP fractions, respectively. TGF-ß1 concentrations increased in PRP vs. PPP, with no changes in PDGF-BB. Discussion: Based on the degree of PLT enrichment and the absence of RBCs and WBCs, this blood product could be classified as a Pure Platelet-Rich Plasma (P-PRP). The presence of GFs in PRP and PPP samples suggests that the PRGF®-Endoret® methodology is suitable for obtaining PRP in FeLV cats, despite future studies are necessary to optimize the technique, standardize the results and assess clinical efficacy.